1. Home
  2. ZTO vs OCEAW Comparison

ZTO vs OCEAW Comparison

Compare ZTO & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZTO
  • OCEAW
  • Stock Information
  • Founded
  • ZTO 2002
  • OCEAW N/A
  • Country
  • ZTO China
  • OCEAW United States
  • Employees
  • ZTO N/A
  • OCEAW 7
  • Industry
  • ZTO Advertising
  • OCEAW Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZTO Consumer Discretionary
  • OCEAW Health Care
  • Exchange
  • ZTO Nasdaq
  • OCEAW Nasdaq
  • Market Cap
  • ZTO N/A
  • OCEAW N/A
  • IPO Year
  • ZTO 2016
  • OCEAW 2021
  • Fundamental
  • Price
  • ZTO $18.81
  • OCEAW $0.02
  • Analyst Decision
  • ZTO Buy
  • OCEAW
  • Analyst Count
  • ZTO 4
  • OCEAW 0
  • Target Price
  • ZTO $25.13
  • OCEAW N/A
  • AVG Volume (30 Days)
  • ZTO 2.9M
  • OCEAW N/A
  • Earning Date
  • ZTO 05-14-2025
  • OCEAW N/A
  • Dividend Yield
  • ZTO 3.67%
  • OCEAW N/A
  • EPS Growth
  • ZTO N/A
  • OCEAW N/A
  • EPS
  • ZTO 1.12
  • OCEAW N/A
  • Revenue
  • ZTO $6,066,599,984.00
  • OCEAW N/A
  • Revenue This Year
  • ZTO $9.23
  • OCEAW N/A
  • Revenue Next Year
  • ZTO $10.36
  • OCEAW N/A
  • P/E Ratio
  • ZTO $16.79
  • OCEAW N/A
  • Revenue Growth
  • ZTO 15.26
  • OCEAW N/A
  • 52 Week Low
  • ZTO $16.34
  • OCEAW N/A
  • 52 Week High
  • ZTO $27.50
  • OCEAW N/A
  • Technical
  • Relative Strength Index (RSI)
  • ZTO 47.84
  • OCEAW N/A
  • Support Level
  • ZTO $18.39
  • OCEAW N/A
  • Resistance Level
  • ZTO $19.08
  • OCEAW N/A
  • Average True Range (ATR)
  • ZTO 0.75
  • OCEAW 0.00
  • MACD
  • ZTO 0.03
  • OCEAW 0.00
  • Stochastic Oscillator
  • ZTO 66.40
  • OCEAW 0.00

About OCEAW Ocean Biomediacal Inc.

Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.

Share on Social Networks: